|Other Names||Folliculin, BHD skin lesion fibrofolliculoma protein, Birt-Hogg-Dube syndrome protein, FLCN, BHD|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP8658b was selected from the C-term region of human FLCN. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||May be a tumor suppressor. May be involved in energy and/or nutrient sensing through the AMPK and mTOR signaling pathways. May regulate phosphorylation of RPS6KB1.|
|Cellular Location||Cytoplasm. Nucleus Note=Mainly localized in the nucleus. Colocalizes with FNIP1 and FNIP2 in the cytoplasm.|
|Tissue Location||Expressed in most tissues tested, including skin, lung, kidney, heart, testis and stomach|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
FLCN may play a role in the pathogenesis of an uncommon form of kidney cancer through its association with an inherited disorder of the hair follicle (fibrofolliculomas). FLCN may be a tumor suppressor. May be involved in colorectal tumorigenesis. It may be involved in energy and/or nutrient sensing through the AMPK and mTOR signaling pathways.
Khoo,S.K., et.al., J. Med. Genet. 39 (12), 906-912 (2002)Shin,J.H., et.al., J. Med. Genet. 40 (5), 364-367 (2003)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.